Paper Details
- Home
- Paper Details
Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study.
Author: ChenHung-Ming, ChenYang-Yuan, HsuYu-Chun, HuangSiou-Ping, LaiJun-Hung, LiuI-Ling, SiaoFu-Yuan, SuPei-Yuan, WuShun-Sheng, YaoChih-Ta, YenHsu-Heng, ZengYa-Huei
Original Abstract of the Article :
Glecaprevir/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated cirrhosis in ...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619604/
データ提供:米国国立医学図書館(NLM)
Glecaprevir/Pibrentasvir: A Promising Treatment for Chronic Hepatitis C-Related Cirrhosis
Chronic hepatitis C, a serious liver disease, has been revolutionized by the development of direct-acting antivirals (DAAs). This research examines the real-world effectiveness and safety of glecaprevir/pibrentasvir, a potent DAA combination, in patients with compensated cirrhosis. The study aimed to evaluate the treatment's efficacy and safety in a real-world setting, reflecting the complexities of clinical practice.
Effective Treatment and Favorable Safety Profile
The study demonstrates the remarkable efficacy and safety of glecaprevir/pibrentasvir in patients with compensated cirrhosis. The results indicate that this DAA regimen can effectively clear the hepatitis C virus and improve liver health, even in patients with underlying liver disease. The findings provide valuable insights into the real-world applicability of this treatment.
Hope for Hepatitis C Patients: A New Era of Treatment
This research offers a ray of hope for individuals battling chronic hepatitis C, particularly those with cirrhosis. The study highlights the potential of glecaprevir/pibrentasvir to improve treatment outcomes and enhance the quality of life for these patients. The findings underscore the importance of continued research and development of new and effective treatments for this challenging disease.
Dr.Camel's Conclusion
Imagine a vast desert, where the relentless sun beats down on the parched earth. Chronic hepatitis C, like a scorching sandstorm, can wreak havoc on the liver. This research brings a refreshing breeze to the desert of hepatitis C treatment, highlighting the efficacy and safety of a new drug combination. The study's findings, like a clear oasis, offer hope for patients facing this debilitating disease, reminding us that even in the most challenging landscapes, new solutions can emerge.
Date :
- Date Completed n.d.
- Date Revised 2021-11-29
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.